Bavituximab Activates CD8+ TILs in a 3D Ex Vivo System of Lung Cancer Patient Derived Tumors With Negative PD-L1 Expression. View presentation
SUNRISE: A Phase III, Randomized, Double-blind, Placebo-Controlled Multi-center Trial of Bavituximab Plus Docetaxel versus Docetaxel Alone in Patients with Previously Treated Stage IIIb/IV Non-Squamous Non-Small-Cell Lung Cancer. View poster
Targeting phosphatidylserine-mediated immune suppression enhances the efficacy of immune checkpoint blockade in pre-clinical tumor models. View presentation
The underlying cause for the failure of current therapies is the persistent and multifocal immune suppression in the tumor microenvironment that drives the absence of pre-existing antitumor T cells. Bavituximab blocks PS-mediated immunosuppression (decreasing MDSCs) by reprograming immune cells in the tumor microenvironment to enhance anticancer activity. Pre-clinical, translational, and clinical results using bavituximab with conventional and immunotherapy combinations promotes a robust, anti-tumor T cell mediated response to enhance cancer therapy.